Finland· FI-REL-REL60660
Trodelvy
A sacituzumab govitecan product containing sacituzumab govitecan, registered in Finland by Orifarm Oy. The same ATC class is registered in 14 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Sacituzumab govitecan is registered in 14 of 19 countries.
Countries holding a registration under ATC L01FX17 (sacituzumab govitecan), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Sacituzumab govitecan · ATC L01FX17
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of sacituzumab govitecan costs, country by country.
Normalised to the WHO defined daily dose (67 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Sacituzumab govitecan · price per daily dose (67 mg)
USD · FX 28 Sept 2026
- CH Switzerland$458.52
The record
At a glance
Fimea (Finland)- Active substance
- Sacituzumab govitecan
- Manufacturer
- Orifarm Oy
- Country
- Finland (FI)
- ATC code
- L01FX17
- ATC class
- Sacituzumab govitecan
- Defined daily dose
- 67 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
60 interactions on record for sacituzumab govitecan.
Graded by severity as the source publishes them — 36 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sacituzumab govitecan · interactions on record
60 records
- 36 severe
- 24 moderate
Most severe, free to view
- FostamatinibB02BX09severe
- CladribineL01BB04severe
- IrinotecanL01CE02severe
- NilotinibL01EA03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Sacituzumab govitecan in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainTRODELVY 200 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONGilead Sciences Ireland Unlimited Company
- CzechiaTRODELVYGilead Sciences Ireland UC, Carrigtohill
- IrelandTrodelvy 200 mg powder for concentrate for solution for infusionGilead Sciences Ireland UC
- IcelandTrodelvyGilead Sciences Ireland UC*
- NorwayTrodelvyGilead Sciences Ireland UC
- PolandTrodelvyGilead Sciences Ireland UC
- BelgiumTrodelvy 200 mgGilead Sciences Ireland UC
- SwedenTrodelvy 200 mg Pulver till koncentrat till infusionsvätska, lösningGilead Sciences Ireland UC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Trodelvy
- Liechtenstein · Trodelvy
- Norway · Trodelvy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2f052d43-6749-46f6-92c9-6405ee19dd6c GET /v1/drugs/2f052d43-6749-46f6-92c9-6405ee19dd6c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "200 mg",
"atc_label": "sasitutsumabigovitekaani",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/21/1592/001",
"fimea_rel_id": "REL60660",
"authorised_at": "2022-09-02"
}See everything about sacituzumab govitecan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.